Uncategorized
FDA grants orphan drug designation to IMCgp100 for uveal melanoma
The FDA granted orphan drug designation to IMCgp100 for the treatment of uveal melanoma.IMCgp100 (Immunocore) is part of a class of bispecific biologic reagents known as ImmTACs, or immune-mobilizing monoclonal T-cell receptors against cancer.